Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ACC 2025: The CardiAMP-HF Trial
Author(s): Amish Raval Added: 1 year ago
ACC 2025 - Principal results from autologous cell therapy in patients with heart failure with reduced ejection fraction (HFrEF) show favourable safety outcomes, however, the study did not meet its primary efficacy outcome using 6 minute walking rests as 3rd F-S tier.Dr Amish Raval (UW Health University Hospital Interventional Cardiology Clinic, WI, US) joins us onsite at ACC to discuss the… View more

Heart Failure
Immune Cell Traits and Aortic Dissection: A Mendelian Randomisation Study
Author(s): Tian-le Li , Mao-long Fu , Li-hong Wang , et al Added: 1 year ago

Electrophysiology & Arrhythmia

Inherited and Congenital Cardiac Conditions
Immune Cell Traits and Heart Failure: A Mendelian Randomisation Study
Author(s): Wei Gao , Hui Wang , Jian-long Wang , et al Added: 7 months ago

Demographic

Heart Failure
Erratum: Causal Characteristics of Immune Cells
Author(s): Tian-le Li , Mao-long Fu , Li-hong Wang , et al Added: 1 year ago
Emerging Toxicities, Translational Research and Reverse Cardio-oncology
Author(s): Massimiliano Camilli , Luca Maggio , Lorenzo Tinti , et al Added: 1 year ago

CV Disease in Special Populations

Heart Failure
Lipid-lowering Therapies and Lp(a)
Author(s): Stephen Nicholls , Adam J Nelson Added: 1 month ago

Prevention & Chronic Conditions
Heart Failure in 2026: Practical Therapy Lessons From ACC.26
Author(s): Felipe Martínez Added: 2 months ago
ACC.26 - In this expert interview filmed at ACC.26 in New Orleans, Prof. Felipe Martínez discusses how late-breaking heart failure data are reshaping contemporary pharmacological management. The conversation focuses on new spironolactone results, advanced hemodynamic strategies in HFpEF, and the expanding role of cardiometabolic therapies, including GLP‑1 receptor agonists, in optimising outcomes… View more

Heart Failure
AHA 25: Beta-Blocker Therapy Post MI in Patients with Preserved LVEF
Author(s): Anna Meta Dyrvig Kristensen Added: 7 months ago
AHA Scientific Sessions 2025 – Dr Anna Meta Dyrvig Kristensen (Copenhagen University Hospital, Bispebjerg and Frederiksberg, DK) presents an individual patient data meta-analysis examining beta-blocker therapy after myocardial infarction in patients with preserved left ventricular ejection fraction.This comprehensive meta-analysis pooled individual patient data from five randomized controlled… View more

Heart Failure
AHA 25: CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3
Author(s): Stephen Nicholls Added: 7 months ago
AHA Scientific Sessions 2025 - Phase 1 results show the CRISPR-Cas9 gene editing therapy is a safe treatment option targeting ANGPTL3 in patients with lipid disorders.Prof Stephen Nicholls (Monash Victorian Heart Institute, Clayton, AU) joins us to share results from a first-in-human phase 1 trial investigating a one-time infusion of CTX310, a CRISPR-Cas9 gene editing therapy, at different doses… View more

Prevention & Chronic Conditions
30th Annual Meeting of the ISCP
Author(s): Maria Fernández García , Alberto Alen Andrés , Beatriz Nieves Ureña , et al Added: 2 months ago

Prevention & Chronic Conditions

CV Disease in Special Populations